TOP＞Investor Relations＞Mid-Term Plan
JCR announced today the five-year mid-term management plan for fiscal years (“FY”) 2015 through FY2019, ending March 31, 2020 (“the Mid-Term Plan”).
In this Mid-Term Plan, we have chosen the word “HIYAKU” (leap into the future) for its key concept as technologies and experiences accumulated to date are beginning to yield results and we are ready to advance toward the next stage. Furthermore, we have selected the following four focal points: (i) Advancing R&D activities one step beyond, (ii) reinforcing our capabilities via new businesses development, (iii) further enhancing “Business Structure” and “Product Strategy”, and (iv) reinforcing “Management Platform” in order to become an R&D oriented specialty pharma with global exposure.
We aim to become an R&D oriented specialty pharma with global exposure built on proprietary biotechnologies and technologies supporting cell therapy and regenerative medicine which we have been developing since foundation.
“HIYAKU”– Now is the time to leap into the future.
In order to advance to become an R&D oriented specialty pharma with global exposure, we will tackle the following focal points:
(i) Advancing R&D activities one step beyond
(ii) Reinforcing our capabilities via new businesses development
(iii) Further enhancing “Business Structure” and “Product Strategy”
(iv) Reinforcing “Management Platform”
In FY2019, which is the last fiscal year covered by the Mid-Term Plan, we aim to achieve sales of 25 billion yen and increase operating profit to 5 billion yen by absorbing the increase in R&D expenses due to the progress of R&D projects.
|FY2018 (Actual results)||FY2019 (Goal)|
|Sales||23.1 billion yen||25 billion yen|
|Operating Profit||4.9 billion yen||5 billion yen|